BLUESTAR GENOMICS INC. (ClearNote Health)
Company Snapshot
Company Overview
Bluestar Genomics Inc. is developing epigenomics-based liquid biopsy diagnostics. The company is actively discovering epigenetic biomarkers for early-stage cancer applications.
Bluestar Genomics has a strong position in proprietary chemistries, bioinformatics and big data for next-generation sequencing.
The early detection of pancreatic cancer via cfDNA was shown to be possible by using a methylation biomarker, 5-hydroxymethylcytosine (5hmC).[23] The researchers concluded that, based on their data, 5hmC changes can allow for classification of PDAC (pancreatic ductal adenocarcinoma) even during early stages of the disease.
Bluestar Genomics is seeking to develop a liquid biopsy test for early-stage PDAC as well as early-stage, pan-cancer tests. The company intends to run these tests as LDTs out of an anticipated CLIA-certified laboratory in San Diego.
BLUESTAR GENOMICS INC. (ClearNote Health) In News
Company's Business Segments
- Liquid Biopsy : The company helps in early detection data for clinicians and their patients having a high risk of developing high-mortality cancers.
Applications/End User Industries
- Healthcare
- Diagnosis
- Life Sciences